Systematic review of available evidence on 11 high-priced inpatient orphan drugs

Systematic review of available evidence on 11 high-priced inpatient orphan drugs

10.1186/1750-1172-8-124

Saved in:

Bibliographic Details
Main Authors:	Kanters, T.A, De Sonneville-Koedoot, C, Redekop, W.K, Hakkaart, L
Other Authors:	SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
Format:	Article
Published:	2020
Subjects:	agalsidase alfa agalsidase beta alemtuzumab canakinumab clofarabine eculizumab fludarabine galsulfase iduronate 2 sulfatase laronidase ofatumumab orphan drug recombinant glucan 1,4 alpha glucosidase trabectedin acute lymphoblastic leukemia article case study chronic lymphatic leukemia CINCA syndrome clinical effectiveness cost effectiveness analysis cost utility analysis drug approval drug cost evidence based medicine Fabry disease hospital patient human mucopolysaccharidosis observational study paroxysmal nocturnal hemoglobinuria quality adjusted life year quasi experimental study soft tissue sarcoma systematic review cost benefit analysis drug manufacture economics Netherlands randomized controlled trial (topic) Rare Diseases standards Cost-Benefit Analysis Humans Inpatients Orphan Drug Production Randomized Controlled Trials as Topic
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/181805
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Description
Summary:	10.1186/1750-1172-8-124